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Evidence suggests that some nonsteroidal anti-
inflammatory drugs (NSAIDs) possess antibacterial
properties with an unknown mechanism. We
describe the in vitro antibacterial properties of the
NSAIDs carprofen, bromfenac, and vedaprofen, and
show that these NSAIDs inhibit the Escherichia coli
DNA polymerase III b subunit, an essential interac-
tion hub that acts as a mobile tether on DNA for
many essential partner proteins in DNA replication
and repair. Crystal structures show that the three
NSAIDs bind to the sliding clamp at a common bind-
ing site required for partner binding. Inhibition of
interaction of the clamp loader and/or the replicative
polymerase a subunit with the sliding clamp is
demonstrated using an in vitro DNA replication
assay. NSAIDs thus present promising lead scaffolds
for novel antibacterial agents targeting the sliding
clamp.
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used
in the treatment of pain, fever, and inflammation (Vonkeman
and van de Laar, 2010). Their mode of action is predominantly
through inhibition of cyclooxygenases to reduce synthesis of
the pro-inflammatory mediator prostaglandin H2 (Dinarello,
2010). Other known targets of NSAIDs in inflammation include
fatty acid amide hydrolase and phospholipase A2 (Singh et al.,
2004, 2009; Bertolacci et al., 2013). Several off-targets unrelated
to inflammation have been identified, including aldo-ketoreduc-
tase 1C3 and retinoid X receptor-a. Binding to these proteins
may explain some of the antiproliferative effects of NSAIDs
(Zhou et al., 2010; Flanagan et al., 2012). Limited data suggest
that NSAIDs possess antibacterial properties, although these
are confounded by routine use of NSAIDs in combination with
antibiotics (Origlieri and Bielory, 2009), particularly in veterinary
medicine (Elitok and Elitok, 2004; Lopez et al., 2007; Kro¨mker
et al., 2011). Weak in vitro antibacterial activity has been demon-
strated by ibuprofen and indomethacin (Shirin et al., 2006;Chemistry & Biology 21,Al-Janabi, 2010), but there has been no report of a mechanism
for this action.
Our studies on the Escherichia coli DNA polymerase III (Pol III)
b subunit led to the discovery that the NSAID carprofen binds to
and inhibits essential interactions of this protein. Pol III b, also
known as the sliding clamp (SC) is a torus-shaped homodimer
that is structurally conserved among all bacterial species (Bur-
nouf et al., 2004; Argiriadi et al., 2006; Gui et al., 2011) and serves
as a protein-protein interaction hub during DNA replication and
repair (Dalrymple et al., 2001; Johnson and O’Donnell, 2005;
Indiani and O’Donnell, 2006). After being loaded onto double-
stranded DNA through interactions with the d subunit of the Pol
III clamp loader complex (composed of Pol III d(g/t)3d
0; Naktinis
et al., 1995; Jeruzalmi et al., 2001; Leu and O’Donnell, 2001),
the SC recruits a diverse range of protein binding partners,
including the a and ε subunits of Pol III; DNA polymerases I, II,
IV, and V; and MutS (Kong et al., 1992; Indiani and O’Donnell,
2006; Jergic et al., 2013). This array of binding partners makes
the SC one of the most trafficked elements in the cell (Bunting
et al., 2003; Lo´pez de Saro, 2009; Robinson et al., 2012). It con-
fers high processivity upon the Pol III aεq core (the replicase) by
acting as a mobile tether (Beck et al., 2006; Kelch et al., 2011).
A single binding pocket containing two subsites (I and II; Bur-
nouf et al., 2004; Georgescu et al., 2008) located on each of the
SC monomers interacts with short linear clamp-binding motifs
(CBMs) located in flexible C-terminal regions or internal loops
of known protein binding partners (Kong et al., 1992; Shamoo
and Steitz, 1999; Dalrymple et al., 2001). Studies have identified
a consensus CBM sequence QLx1Lx2F/L (where x is any amino
acid; S or D preferred at x1; x2 may be absent) that interacts with
the SC CBM-binding pocket, and isolated peptides based on
this sequence bind the SC with affinities similar to their parent
proteins (Wijffels et al., 2004, 2011). Conversely, when CBMs
are removed from parent proteins, they are observed to lose
affinity for the SC (Dalrymple et al., 2001; Kongsuwan et al.,
2006).
Targeting the bacterial DNA replication machinery is a vali-
dated strategy for producing clinically useful antibiotics, as
evidenced by the highly successful quinolones, DNA gyrase in-
hibitors (Kohanski et al., 2010). The bacterial SC is an emerging
DNA replication target that is yet to be clinically validated (Rob-
inson et al., 2012). Modified peptides based on the consensus
sequence show increased affinity to the clamp (Wolff et al.,
2011; Wijffels et al., 2011). Small molecules have been identified481–487, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 481
Table 1. E. coli SC Binding Properties and Antibacterial Activities of Selected NSAIDs
NSAID
E. coli SC Inhibition
MICa
E. coli A. baylyi S. aureus B. subtilis
IC50 (mM) Ki
b (mM) mM mg/ml mM mg/ml mM mg/ml mM mg/ml
Vedaprofen 222 131 5,000 1,410 2,500 705 156 44 156 44
Bromfenac 328 193 2,500 835 5,000 1,670 2,500 835 1,250 418
Carprofen 481 283 2,500 680 1,250 340 313 85 313 85
Flufenamic acid 1,300 750 >5,000 >1,400 5,000 1,400 625 175 313 88
Tolfenamic acid 1,500 900 >5,000 >1,300 5,000 1,300 625 163 313 82
See also Tables S1–S3 and Figure S1.
aMIC was determined as the lowest NSAID concentration giving a background-corrected OD595 < 0.1 after 24 hr of bacterial growth.
bKi is calculated from IC50 values using the Kenakin correction for ligand depletion (Kenakin, 1993).
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Antibacterial Mechanism of NSAIDsthat bind to the CBM-binding pocket of the SC and inhibit inter-
actions with polymerases, but no antibacterial activities have yet
been reported (Georgescu et al., 2008; Wijffels et al., 2011).
These are RU7, a thioxothiazolinine derivative (Georgescu
et al., 2008), and a biphenyloxime ether derivative (Wijffels
et al., 2011). Both classes of compound bind in subsite I of the
CBM-binding cleft. Our observation of the ability of the NSAID
carprofen, described below, to bind to the identical site on the
SC spurred us to initiate a broader exploration of the effects of
NSAIDs on the SC. Minimal inhibitory concentrations (MICs)
were measured for a variety of NSAIDs to establish a correlation
between SC binding and inhibition and in vitro antibacterial
potencies. Biochemical assays using a minimal set of compo-
nents for SC-dependent DNA replication were used to demon-
strate inhibitory effects of NSAIDs on this essential process,
and X-ray crystallography provided structural insights into
NSAID-SC binding.
RESULTS
SC Inhibition and Antibacterial Potency
A fluorescence polarization (FP) competition assay (Yin et al.,
2013) was used to assess the E. coli SC binding affinity of
commercially available NSAIDs. A fluorescently labeled tracer
peptide (5-carboxyfluorescein-QLDLF) based on the N-acety-
lated consensus pentapeptide AcQLDLF (Wijffels et al., 2011;
Wolff et al., 2011) was used as the competitor ligand. Inhibition
of tracer binding to the SC at various NSAID concentrations
gave half-maximal inhibitory concentration (IC50) values that
were transformed into inhibition constants (Ki) using the Kenakin
correction for ligand depletion (Kenakin, 1993). Twenty NSAIDs
were tested (Table S1 available online), with five showing Ki
values in the high micromolar range (Table 1; Figure S1). Vedap-
rofen, bromfenac, and carprofen showed the strongest effects
(Ki < 300 mM), while flufenamic and tolfenamic acidswereweaker
binders (Ki values > 700 mM).
NSAIDs were tested for antibacterial activity using standard
MIC assays with four species: E. coli, Acinetobacter baylyi,
Staphylococcus aureus, and Bacillus subtilis. MICs evaluated
as inhibited visible growth with varying concentrations of
NSAIDs are provided in Table S1. The Gram-positive species
(S. aureus and B. subtilis) showed higher susceptibility to
NSAIDs than the Gram-negative species (E. coli and A. baylyi),
a trend also observed with four positive control antibiotics (Table482 Chemistry & Biology 21, 481–487, April 24, 2014 ª2014 ElsevierS2). The additional permeability barrier of the outer membrane in
Gram-negative species is likely responsible for these trends
(Rigel and Silhavy, 2012).
The antibacterial testing was repeated for the top-five SC
inhibitors, vedaprofen, bromfenac, carprofen, and flufenamic
and tolfenamic acids. The MICs were determined as lowest
NSAID concentration with background-corrected optical density
of less than 0.1 after 24 hr bacterial growth (Table S3). The result-
ing MICs (Table 1; data derived from Table S3) are consistent
with results from visual inspections. These five NSAIDs that
most potently inhibited E. coli SC binding in the FP assay were
the same compounds that showed the highest level of antibac-
terial activity against Gram-positive species and were the only
NSAIDs to show any activity against the Gram-negative species.
NSAIDs that did not inhibit the E. coli SC all showed very low or
negligible antibacterial activity (Table S1), consistent with inhibi-
tion of the SC giving rise to the antibacterial effects of NSAIDs.
The consensus pentapeptide AcQLDLF (Wolff et al., 2011)
showed high affinity for the E. coli SC (Ki1 mM), but no antibac-
terial activity (Table S1), likely due to its inability to penetrate
bacterial membranes (Bechara and Sagan, 2013) and/or sus-
ceptibility to aminopeptidase activity (Gonzales and Robert-
Baudouy, 1996).
NSAIDs Inhibit theE. coli SC through Binding to Subsite I
of the CBM-Binding Pocket
The locations of binding of NSAIDs to the E. coliSCwere demon-
strated by X-ray crystallography. NSAID/E. coli SC co-crystal
structures were obtained with each of the best SC binders,
vedaprofen, bromfenac, and carprofen. These complexes are
denoted as SCVedaprofen, SCBromfenac, and SCCarprofen. All three
NSAIDs were found to bind in subsite I of the CBM-binding
pocket (Figure 1). Interestingly, while crystals were soaked in
the presence of racemic mixtures of vedaprofen and carprofen,
the 2mFo-DFc electron density maps suggested that (R)-vedap-
rofen and (S)-carprofen were the favored stereoisomers in the
complexes (Figures 1A and 1C). Superimpositions of the
NSAID-bound structures and their corresponding native crystal
structures (obtained in the same crystal form) are shown in Fig-
ures 1A–1C. Stereo diagrams of these complex structures are
shown in Figure S1.
The cyclohexyl moiety of (R)-vedaprofen occupies a deep hy-
drophobic pocket in subsite I comprising the side chains of
V247, L177, V360, and M362 (Figure 1A). The naphthalene ringsLtd All rights reserved
Figure 1. X-Ray Crystal Structures Showing NSAIDs Bound to Subsite I of the CBM-Binding Pocket of the E. coli Sliding Clamp
Complexes are represented with the SC and NSAID carbon atoms in shaded light green. (R)-vedaprofen (A), bromfenac (B), and (S)-carprofen (C). All other atoms
are represented in CPK colors. Apo-SC structures (Yin et al., 2013; PDB entries 4K3P chain B in A and 4K3S chain A in B and C, shown in orange) are super-
imposed for comparison. Pairs of H-bonded atoms are indicated with dashed red lines. Electron density maps (2mFo–DFc) contoured at 1s are shown in blue
wire-basket form.
See Figure S1 for stereo views and Table S4 for crystallographic details.
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(R)-vedaprofenmoved the side chains of R246 andR240 (relative
to the apo-SC structure) toward the (R)-vedaprofen carboxylate,
resulting in formation of a salt bridge between the carboxylate
and the guanidinium moiety of R240. The side chain of V247
adopted a flipped conformation relative to the apo structure,
apparently as a result of steric interactions with the bulky cyclo-
hexane group. Additionally, the cyclohexyl ring caused rotation
of the c2 angle of M362, a residue that acts as a ‘‘gate’’ between
subsites I and II, from130 to69. The side chain of S346was
also rotated in response to movements in M362.
The aryl bromide of bromfenac occupies the deep hydropho-
bic pocket of subsite I, with the aniline group residing in the
adjacent shallower region (Figure 1B). The carboxylate of brom-
fenac makes no direct interactions with the binding site. Binding
of bromfenac caused only minor structural perturbations in
subsite I with the exception of a rotated side chain at S346.
The ‘‘gating’’ residue M362 retained the ‘‘closed’’ conformation
(c2 of 171), as observed in the apo-SC structure.
In the case of (S)-carprofen, the carbazole ring occupies the
shallower region and the aryl chloride is buried in the adjacent
deep pocket (Figure 1C). The carboxylate group of (S)-carprofen
forms an H-bond with the side chain phenol of Y154. The carba-
zole nitrogen is oriented outward from the binding site and this
pose appears to open the M362 gate, rotating its c2 angle from
174 to 58. The only other change observed in subsite I is
the rotation of the side chain of S346.
The E. coli SCCBM-Binding Pocket Is Conserved across
Bacterial Species
Sequence alignments of the SCs (Figure 2A) from the four bacte-
rial species used in the antibacterial assays show that the 15
residues comprising subsites I (yellow) and II (cyan) of their
respective CBM-binding pockets are very well conserved, espe-
cially in subsite I. Sequence alignments of the SCs from a total of
nine bacterial species (five Gram-negative species and fourChemistry & Biology 21,Gram-positive species) similarly showed highly conserved
CBM-binding pocket sequences (Figure S2).
The structures of SCCarprofen and the E. coli SC in complex with
the Pol III d subunit (Protein Data Bank [PDB] entry 1JQJ; Jeru-
zalmi et al., 2001) are overlaid in Figure 2B. Similarly, the struc-
tures of SCCarprofen and the SC in complex with the C-terminal
CBM-peptide of the Pol III a subunit (PDB entry 3D1F; Geor-
gescu et al., 2008) are overlaid in Figure 2C. The structures
show that binding of the CBMs of both Pol III d and a subunits
span subsites I and II, with the LxF submotif of each peptide
filling the pocket at subsite I occupied by the NSAIDs (Figures
1A and 1B). High sequence conservation within the CBM-bind-
ing pockets of the various SC homologs suggests that these
NSAIDs most likely bind to subsite I and inhibit the SCs of
many bacterial species.
NSAIDs Inhibit In Vitro DNA Replication
An SC-dependent DNA replication assay using a minimal set of
components required for in vitro DNA replication was developed
to explore inhibition of the E. coli SC by NSAIDs. In this assay,
binding of CBMs from the d and a subunits to the SC are essen-
tial for replication, meaning impaired SC binding due to the
presence of NSAIDs will inhibit DNA synthesis. A synthetically
RNA-primed circular single-stranded (ss) DNA coated with ss
DNA-binding protein (SSB) was used as a template. The reaction
system (Jergic et al., 2013) contained the SC, the Pol III a sub-
unit, and a reconstituted clamp loader complex (g3dd
0) to load
the SC at the primer terminus (Figure 3A). The a subunit bound
to the SC catalyzes extension of the primer through incorpora-
tion of deoxyribonucleoside triphosphates (dNTPs) using the
ssDNA as template. Formation of double-stranded DNA was
tracked by agarose gel electrophoresis and is dependent on
the SC concentration (Figures S3A and S3B).
As a positive control, the pentapeptide AcQLDLF (Ki 1 mM;
used as a model inhibitor) showed dose-dependent inhibition
of replication over the range of 1–10 mM (Figure 3B), when added481–487, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 483
Figure 2. NSAIDs at the CBM Binding Site of the E. coli SC
(A) Sequence alignments of SCs from the four bacterial species. Residues
comprising subsites I (yellow) and II (cyan) of the CBM-binding pockets
(numbering based on the E. coli sequence) are highlighted. See also Figure S2.
(B and C) Superimposition of the structures of the E. coli SC in complex with
(B) (S)-carprofen and the CBM of Pol III d (PDB entry 1JQJ; Jeruzalmi et al.,
2001) and (C) (S)-carprofen and the C-terminal CBM peptide of Pol III a (PDB
entry 3D1F; Georgescu et al., 2008). The SC and (S)-carprofen carbon atoms
are in shaded light green. The SC carbon atoms in PDB entries 1JQJ and 3D1F
are in blue with the carbon atoms of the Pol III d and a subunits in orange and
pink, respectively. All other atoms are represented in CPK colors. Only the
residues of the d and a subunits that interact with subsites I and II are shown for
clarity.
Figure 3. NSAIDs Inhibit In Vitro DNA Replication
(A) Components of the replication assay.
(B–E) Inhibition of DNA synthesis by AcQLDLF (B), and NSAIDs vedaprofen (C),
bromfenac (D), and carprofen (E). The ssDNA template is converted to a
double-stranded circular product, as indicated.
See also Figure S3.
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out by pre-incubating the reaction system before the addition
of the a subunit and the AcQLDLF pentapeptide, hoping to
distinguish the inhibition of DNA synthesis from the inhibition of
clamp loading (Figure S3C). However, two experiments yielded
similar inhibition profiles, suggesting that ongoing synthesis by
a from a preloaded SC is at least as sensitive to inhibition as
clamp loading. The reversible nature of clamp-loading (Leu
et al., 2000) also provides a plausible explanation for the similar
profiles—the addition of an inhibitor followed by equilibration of484 Chemistry & Biology 21, 481–487, April 24, 2014 ª2014 Elsevierthe clamp-loading and unloading process erases the effects of
pre-incubation.
NSAIDs were titrated into the total reaction system at concen-
trations up to 1mM (Figures 3C–3E). Vedaprofen and bromfenac
completely inhibited replication at 500 mM, while showing no
effects below 63 mM. Carprofen showed weaker effects consis-
tent with its weaker affinity for the SC (Table 1), producing com-
plete inhibition at 1 mM. Inhibitory potencies of NSAIDs in the
DNA replication assay were approximately 100-fold less than
those for AcQLDLF, consistent with their 100-fold weakerLtd All rights reserved
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binders flufenamic and tolfenamic acids and the non-SC binding
NSAID ibuprofen showedmuch weaker effects or no inhibition of
DNA replication (Figures S3D and S3E).
DISCUSSION
There is a pressing need for new classes of antibiotics (Bassetti
et al., 2013). The bacterial SC is an emerging target for the devel-
opment of new antibacterial agents (Georgescu et al., 2008;
Wijffels et al., 2011). Its structure is highly conserved: studies
indicate that clamps from several bacterial species have similar
overall structures and CBM-binding sites (Burnouf et al., 2004;
Argiriadi et al., 2006; Gui et al., 2011). This study demonstrates
that some NSAIDs are able to block subsite I, preventing SC
binding to Pol III d and/or a subunits and causing inhibition of
DNA replication in vitro. Bacterial DNA replication in vivo is highly
complex and involves many interacting components (Kelman
and O’Donnell, 1995; Pomerantz and O’Donnell, 2007). By
simplifying replication to a requirement for just four essential
components, the SC, the clamp loader complex, the Pol III a
subunit, and SSB (Jergic et al., 2013), we were able to directly
link inhibition of SC-mediated interactions by NSAIDs to inhibi-
tion of DNA replication in vitro, thus providing an explanation
for the apparent correlation between E. coli SC inhibition and
antibacterial effects. Because the CBM-binding pocket is well
conserved across bacteria, E. coli SC inhibitors like vedaprofen,
bromfenac, and carprofen would also be expected to bind SCs
from other species. All three were shown to be relatively weak
inhibitors of the E. coli SC, consistent with their modest antibac-
terial activity compared to standard antibiotics. It is noteworthy
that bromfenac demonstratedmuchweaker antibacterial activity
against Gram-positive species than vedaprofen and carprofen.
Furthermore, flufenamic and tolfenamic acids exhibited similar
antibacterial effects to carprofen despite apparent weak SC
affinity. These observations could be explained in part by
differing membrane permeability and differences in the SC affin-
ities of those compounds in the different species. While vedap-
rofen and carprofen have been used as adjuvants to antibiotics
for their anti-inflammatory effects in the treatment of veterinary
bacterial infections (Elitok and Elitok, 2004; Lopez et al., 2007;
Kro¨mker et al., 2011), the current work suggests that their co-
administration may actually contribute independent (or perhaps
synergistic) antibacterial effects.
The X-ray structures here, showing that the three NSAIDs bind
in subsite I, should provide valuable insights into the design of
more potent small-molecule SC inhibitors, potentially leading
to the discovery of new classes of antibiotics with a novel mech-
anism of action. The conserved nature of the SC across bacterial
species suggests potent SC inhibitors might show broad-spec-
trum activity. All three NSAIDs were shown to bury a hydropho-
bic moiety into the deep pocket of subsite I while positioning an
aromatic ring(s) in the adjacent and shallower region. The three
NSAIDs all contained carboxylic acids, which can form salt-
bridges or H-bonds with adjacent residues; however, these in-
teractions appeared to be confined to the edge of subsite I
and did not seem to be a prerequisite for binding. Whereas all
three NSAIDs fully occupied subsite I, their relatively weak bind-
ing suggests there is only limited potential for designing moreChemistry & Biology 21,potent SC inhibitors that target subsite I alone. Of the three
NSAIDs, only carprofen adopted a binding pose that ‘‘opened’’
the M362 gate separating the two subsites, inducing a CBM-
binding pocket structure similar to that observed upon binding
of peptide CBMs. It was also noted that the carbazole nitrogen
of carprofen is directed toward subsite II, suggesting it might
be a useful synthetic handle for projecting extra functionality
toward this subsite in searching for nonpeptidic SC-binders
with higher affinity.
SIGNIFICANCE
New classes of antibiotics operating through novel targets
are of great interest. The sliding clamp represents an
emerging target for new antibacterial agents—interactions
between DNA polymerases and sliding clamps are essential
to ensure DNA replication and cell proliferation. Sliding
clamp inhibitors have been reported, but none are yet used
therapeutically. We report antibacterial activity of members
of an established drug class, the nonsteroidal anti-inflam-
matory drugs (NSAIDs) against Gram-negative and Gram-
positive bacteria, and link those activities to inhibition of
sliding clamps.
EXPERIMENTAL PROCEDURES
Compounds and Peptides
NSAIDs (purity > 95%) were purchased from Vitas-M Laboratory, Labotest, or
Sigma-Aldrich. Peptides were custom synthesized byGLBiochem (China) and
showed >95% purity, as confirmed by high-performance liquid chromatog-
raphy-mass spectrometry.
Protein Expression and Purification
Expression and purification of the E. coli SC, Pol III a subunit, SSB, and the
clamp loader complex g3dd
0 were carried out as described previously (Wijffels
et al., 2004; Mason et al., 2013; Jergic et al., 2013).
Crystallization and X-Ray Data Collection
Crystals of the E. coli SC were grown at 285 K by the hanging-drop vapor
diffusion method. The drop was composed of 1 ml of sliding clamp
(53 mg/ml in 10 mM Tris-HCl pH 7.2, 1 mM dithiothreitol, 1 mM EDTA, and
15% glycerol) mixed with an equal volume of reservoir solution consisting of
100 mM 2-(N-morpholino) ethanesulfonic acid buffer pH 6.5, 100–150 mM
CaCl2, and 25%–30% (v/v) PEG400.The reservoir volume was 1 ml. SC crys-
tals were transferred to a CaCl2-free reservoir solution and ligands were
soaked into the crystal at 2–5 mM in reservoir solution with <10% DMSO. All
crystals were mounted using MiTeGen loops on pins with magnetic caps.
For in-house data collection, crystals were flash-frozen to 100 K using an
Oxford Cryo-stream. Diffraction data were collected using a MAR345 desktop
beamline using CuKa X-rays from a Rigaku 007HF rotating anode generator
with Varimax optics. For synchrotron data collection, the SSRL automated
mounting system (SAM)was used.Mounted crystals were flash-frozen in liquid
nitrogen and placed in the SAM cassettes. Diffraction data were collected at
100 K at the Australian Synchrotron, BeamlineMX1 using X-rays of wavelength
0.95 A˚.
Data Processing, Structure Solution, and Refinement
Crystal data sets were integrated, merged, and scaled with either HKL2000
(Otwinowski and Minor, 1997) or MOSFLM and SCALA (Winn et al., 2011)
The structures were solved by molecular replacement with CCP4 using the
PDB entry 1MMI (Oakley et al., 2003) or 4K3S (Yin et al., 2013) as the starting
model. Iterative cycles of model building and refinement were performed in
COOT (Emsley and Cowtan, 2004) and REFMAC5 (Skuba´k et al., 2004).481–487, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 485
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Sequence alignment of bacterial sliding clamps (Gene Expression Onmibus
IDs: YP_859300.1, WP_004930066.1, ZP_05582848.1, ZP_08441263.1, NP_
064722.1, NP_373240.1, WP_003242509.1, YP_815419.1, and AAF98349.2)
was carried out using COBALT (Papadopoulos and Agarwala, 2007).
Fluorescence Polarization Assay
FP experiments followed the published protocol (Yin et al., 2013). Brifely, All
FP experiments were conducted using a POLARstar Omega plate reader
with nontreated black sterile 96-well plates (Greiner). The buffer contained
10 mM HEPES pH 7.4, 1 mM EDTA, 1 mM dithiothreitol, 0.07% Nonidet
P-40, and 5% DMSO. The fluorescent tracer used was N-fluorescein (FAM)-
QLDLF-OH (GL Biochem), which has a Kd of 70 nM for SC monomers. For
the competition assay, 10 nM peptide and 50 nM sliding clamp monomers
were used. Blank control (buffer), negative control (buffer and the peptide),
and positive control (buffer, peptide, and the sliding clamp) were used for
data standardization. Experiments were carried out in duplicate. Curves
were fit using GraphPad Prism v5.01 (GraphPad Software). Binding-saturation
curve fitting was applied to tracer binding. Dose-response curve fitting was
applied to competition assays with variable slope.
Antibacterial Activity
Determination of MICs was carried out with the four bacterial strains
Acinetobacter baylyi ADP1, Escherichia coli K12 MG1655, Staphylococcus
aureus NCTC8325, and Bacillus subtilis 168. Experiments followed the
Clinical and Laboratory Standards Institute broth microdilution method
(CLSI, 2009). Briefly, bacteria were grown overnight and inoculated at
5 3 104 colony-forming units/ml into cation-adjusted Mueller Hinton II
broth. Serial 2-fold dilution of NSAID compounds or antibiotics was carried
out in sterile 96-well plates. Controls of the growth medium only (blank
controls), inoculated medium (negative controls), and inoculated medium
with antibiotics (as positive controls) were used. Tests were carried out
with 20 NSAIDs and four antibiotics, where MICs were defined as the
lowest concentration of compound to inhibit visible growth after incubation
for 24 hr at 37C. For vedaprofen, bromfenac, carprofen, and flufenamic
and tolfenamic acids, optical density values of inoculated cultures were
measured at wavelength 595 nm (OD595) as the background using a plate
reader (Tecan Infinite M200 Pro). The plates were incubated for 24 hr at
37C and then the OD595 values were measured again; MICs were defined
as the lowest compound concentration with background-subtracted
OD595 < 0.1.
DNA Replication Assay
The RNA-primed DNA template was prepared in advance by mixing
35 nM wild-type M13 ssDNA (Jergic et al., 2013) with 1 mM oligoribonucleo-
tide (50-UAUGUACCCCGGUUGAUAAUCAGAAAAGCCCCA; GeneWorks) in
30 mM Tris-HCl pH 7.6, 15 mM MgCl2, 130 mM NaCl, and 0.1 mM EDTA
for 10 min at 55C and cooling to room temperature over 8 hr. DNA
replication assays contained 20 mM Tris-HCl pH 7.6, 10 mM MgCl2,
0.8 mM ATP, 8.4 mM dithiothreitol, 0.6 mM of each dNTP, 211 nM Pol III
a subunit, 700 nM SSB (as tetramers), 210 nM Pol III b subunit (as dimers),
42 nM g3dd
0 clamp loader complex, 120 mM NaCl, and 3 nM RNA primed
DNA template, in a volume of 6.8 ml. Compounds/peptide were dissolved
in DMSO and diluted in series 2-fold (in 50% v/v DMSO) before being
added (0.5 ml) to the assay mixture at 0C. The final DMSO concentration
was 3.4% (v/v) in all assays. The assay mixtures were treated at 30C
for 60 min before being quenched by the addition of EDTA to 150 mM
and SDS to 1% (w/v). The DNA products were separated by 0.7% agarose
gel electrophoresis in TAE buffer (80 mM Tris, 40 mM acetic acid, and
4 mM EDTA) and then stained with 10,000-fold diluted SYBR Gold (Life
Technologies) for 60 min. The DNA products were visualized using a UV
transilluminator.
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